Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2024-10-19
DOI
https://doi.org/10.1093/oncolo/oyae256
Citations
7
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
4.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

Lorenzo Antonuzzo, Silvia Camera, Stefano Tamberi, Tiziana Pressiani et al.
7 citations
The Oncologist
Cholangiocarcinoma and Gallbladder Cancer Studies
4.01
article

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

Lorenzo Antonuzzo, Silvia Camera, Stefano Tamberi, Tiziana Pressiani, Guido Giordano, Monica Verrico, Oluseyi Abidoye, Francesca Salani, Emiliano Tamburini, Margherita Rimini, Masafumi Ikeda, Alessandro Pastorino, Fabian Finkelmeier, Federica Lo Prinzi, Il Hwan Kim, Alessandro Parisi, Monica Niger, Valentina Zanuso, Mario Scartozzi, Gerald W. Prager, Lukas Perkhofer, Ricardo Roque, Lorenzo Fornaro, Caterina Vivaldi, Florian Castet, Gian Paolo Spinelli, Min-Su Kang, Ilario Giovanni Rapposelli, Matteo Landriscina, Stephen L. Chan, Chiara Braconi, Marta Schirripa, Anna Diana, Jessica Lucchetti, Sara Lonardi, Jorge Adeva, Vera Himmelsbach, Mario Domenico Rizzato, Alessandra Boccaccino, Hanne Vandeputte, Gianluca Masi, Giuseppe Tonini, Nicola Personeni, Lucrezia Silvestro, Maria Grazia Rodriquenz, Ester Oneda, Federico Rossari, Lorenza Rimassa, Hong Jae Chon, Ingrid Garajová, Daniele Lavacchi, Jeroen Dekervel, Luca Esposito, Chiara Pircher, Cecilia Melo Alvim, Tanios Bekaii‐Saab, Selma Ahcene Djaballah, Tomoyuki Satake, Rita Balsano, Antonio Avallone, Changhoon Yoo, Jin Won Kim, Antonio De Rosa, Andrea Casadei‐Gardini, Silvana Leo, Massimo Viola
article en
7 citations

Abstract

Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.

The OncologistVol. 30(3)
University of Foggia (IT), University of Pisa (IT), Goethe University Frankfurt (DE), Ulsan College (KR), Marche Polytechnic University (IT), University of Parma (IT), Humanitas University (IT), University of Padua (IT), Vita-Salute San Raffaele University (IT), Università Campus Bio-Medico (IT), University of Cagliari (IT), Chinese University of Hong Kong (HK), Casa Sollievo della Sofferenza (IT), Policlinico Umberto I (IT), Beatson West of Scotland Cancer Centre (GB), WinnMed (US), New Generation University College (ET), Seoul National University Bundang Hospital (KR), Brescia University (US), University of Ulsan (KR), Ospedali Riuniti di Foggia (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Ospedale di Cattinara (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Inje University Haeundae Paik Hospital (KR), Istituto Oncologico Veneto (IT), Prince of Wales Hospital (CN), National University College (PR), Vall d'Hebron Hospital Universitari (ES), Ospedale di Belcolle (IT), University Hospital Frankfurt (DE), CHA University Bundang Medical Center (KR), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Campus Bio Medico University Hospital (IT), Spanish Society of Hematology and Hemotherapy (ES), National Cancer Center Hospital East (JP), Ospedale Policlinico San Martino (IT), Mayo Clinic in Florida (US), Fondazione Poliambulanza Istituto Ospedaliero (IT), CHA University (KR), Hospital de Santa Maria (PT), Molecular Oncology (United States) (US), Ospedale Vito Fazzi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University Hospital Ulm (DE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), Vall d'Hebron Institute of Oncology (ES), University of Florence (IT), Medical University of Vienna (AT), University of Glasgow (GB), Sapienza University of Rome (IT), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 6%
Cholangiocarcinoma and Gallbladder Cancer Studies
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.